




Europäisches  
Patentamt

European  
Patent Office

Office européen  
des brevets



Bescheinigung

Certificate

Attestation

Die angehefteten Unterla-  
gen stimmen mit der  
ursprünglich eingereichten  
Fassung der auf dem näch-  
sten Blatt bezeichneten  
europäischen Patentanmel-  
dung überein.

The attached documents  
are exact copies of the  
European patent application  
described on the following  
page, as originally filed.

Les documents fixés à  
cette attestation sont  
conformes à la version  
initialement déposée de  
la demande de brevet  
européen spécifiée à la  
page suivante.

Patentanmeldung Nr. Patent application No. Demande de brevet n°

02028609.2

**PRIORITY  
DOCUMENT**  
SUBMITTED OR TRANSMITTED IN  
COMPLIANCE WITH RULE 17.1(a) OR (b)

Der Präsident des Europäischen Patentamts;  
Im Auftrag

For the President of the European Patent Office

Le Président de l'Office européen des brevets  
p.o.

R C van Dijk

BEST AVAILABLE COPY



Anmeldung Nr:  
Application no.: 02028609.2  
Demande no:

Anmeldetag:  
Date of filing: 20.12.02  
Date de dépôt:

Anmelder/Applicant(s)/Demandeur(s):

DeveloGen Aktiengesellschaft für  
entwicklungsbiologische Forschung  
Rudolf-Wissell-Strasse 28  
37079 Göttingen  
ALLEMAGNE

Bezeichnung der Erfindung/Title of the invention/Titre de l'invention:  
(Falls die Bezeichnung der Erfindung nicht angegeben ist, siehe Beschreibung.  
If no title is shown please refer to the description.  
Si aucun titre n'est indiqué se référer à la description.)

(PPM 1D) Protein phosphatase 2C homologous proteins involved in the regulation of  
energy homeostasis

In Anspruch genommene Priorität(en) / Priority(ies) claimed / Priorité(s)  
revendiquée(s)  
Staat/Tag/Aktenzeichen/State/Date/File no./Pays/Date/Numéro de dépôt:

Internationale Patentklassifikation/International Patent Classification/  
Classification internationale des brevets:

A61K38/00

Am Anmeldetag benannte Vertragstaaten/Contracting states designated at date of  
filing/Etats contractants désignées lors du dépôt:

AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LI LU MC NL PT SE SI SK

20. Dez. 200

# WEICKMANN & WEICKMANN

Patentanwälte,  
European Patent Attorneys · European Trademark Attorneys

EPO - Munich  
5

20. Dez. 2002

Unser Zeichen:  
29632P EP/WWId

Anmelder:  
DeveloGen Aktiengesellschaft für  
entwicklungsbiologische Forschung  
Rudolf-Wissell-Straße 28

37079 Göttingen  
DEUTSCHLAND

DIPL.-ING. H. WEICKMANN (bis 31.1.01)  
DIPL.-ING. F. A. WEICKMANN  
DIPL.-CHEM. B. HUBER  
DR.-ING. H. LISK  
DIPL.-PHYS. DR. J. PRECHTEL  
DIPL.-CHEM. DR. B. BOHM  
DIPL.-CHEM. DR. W. WEISS  
DIPL.-PHYS. DR. J. TIESMEYER  
DIPL.-PHYS. DR. M. HERZOG  
DIPL.-PHYS. B. RUTTENSPERGER  
DIPL.-PHYS. DR.-ING. V. JORDAN  
DIPL.-CHEM. DR. M. DEY  
DIPL.-FORSTW. DR. J. LACHNIT

---

(PPM1D) Protein phosphatase 2C homologous proteins involved in the  
regulation of energy homeostasis

---

**(PPM1D) Protein phosphatase 2C homologous proteins involved in the regulation of energy homeostasis**

**Description**

5.

10

This invention relates to the use of nucleic acid sequences encoding protein phosphatase 2C homologous proteins, and the polypeptides encoded thereby and to the use thereof or effectors of said nucleic acid sequences or polypeptides in the diagnosis, study, prevention, and treatment of metabolic diseases or dysfunctions, for example, but not limited to, such as metabolic syndrome including obesity, diabetes mellitus, eating disorder, cachexia, hypertension, coronary heart disease, hypercholesterolemia (dyslipidemia), and gallstones.

15

20

25

There are several metabolic diseases of human and animal metabolism, e.g., obesity and severe weight loss, that relate to energy imbalance where caloric intake versus energy expenditure is imbalanced. Obesity is one of the most prevalent metabolic disorders in the world. It is still a poorly understood human disease that becomes as a major health problem more and more relevant for western society. Obesity is defined as a body weight more than 20% in excess of the ideal body weight, frequently resulting in a significant impairment of health. Obesity may be measured by body mass index, an indicator of adiposity or fatness. Further parameters for defining obesity are waist circumferences, skinfold thickness and bioimpedance (see, inter alia, Kopelman (1999), loc. cit.). It is associated with an increased risk for cardiovascular disease, hypertension, diabetes mellitus Type II, hyperlipidaemia and an increased mortality rate. Besides severe risks of illness, individuals suffering from obesity are often isolated socially.

30

Obesity is influenced by genetic, metabolic, biochemical, psychological, and behavioral factors and can be caused by different reasons such as non-insulin dependent diabetes, increase in triglycerides, increase in carbohydrate bound energy and low energy expenditure. As such, it is a complex disorder that must be addressed on several fronts to achieve lasting positive clinical outcome. Since obesity is not to be considered as a single disorder but as a heterogeneous group of conditions with (potential) multiple causes, it is also characterized by elevated fasting plasma insulin and an exaggerated insulin response to oral glucose intake (Koltermann J., (1980) Clin. Invest 65, 1272-1284). A clear involvement of obesity in type 2 diabetes mellitus can be confirmed (Kopelman P.G., (2000) Nature 404, 635-643).

Triglycerides and glycogen are used as the body's fuel energy storage. Glycogen is a large branched polymer of glucose residues that is mainly stored in liver and muscle cells. Glycogen synthesis and degradation is central to the control of the blood glucose level.

Triglycerides are stored in the cytoplasm of adipocytes. Adipocytes are specialized for the synthesis, storage and mobilization of triglycerides. The glycogen and triglyceride metabolism is highly regulated and their interplay is essential for the energy homeostasis of the body. A high glucose level in the adipose cell results in the synthesis of triglycerides as fuel store. A low intracellular glucose level leads to a release of fatty acids, which can be used as substrates for the beta-oxidation to generate energy. Glycogen levels in cells are more variable than triglyceride levels because the turnover of glycogen is higher. Triglycerides are used as long term energy donors once the glycogen stores run low.

Hyperlipidemia and elevation of free fatty acids correlate clearly with the 'Metabolic Syndrome', which is defined as the linkage between several diseases, including obesity and insulin resistance. This often occurs in the

same patients and is a major risk factor for development of Type 2 diabetes and cardiovascular disease. It was suggested that the control of lipid levels and glucose levels is required to treat Type 2 Diabetes, heart disease, and other occurrences of Metabolic Syndrome (see, for example, Santomauro A. T. et al., (1999) Diabetes, 48(9):1836-1841).

The molecular factors regulating food intake and body weight balance are incompletely understood. Even if several candidate genes have been described which are supposed to influence the homeostatic system(s) that regulate body mass/weight, like leptin, VCPI, VCPL or the peroxisome proliferator-activated receptor-gamma co-activator, the distinct molecular mechanisms and/or molecules influencing obesity or body weight/body mass regulations are not known. In addition, several single-gene mutations resulting in obesity have been described in mice, implicating genetic factors in the etiology of obesity (Friedman J. M. and Leibel R. L., (1992) Cell 69(2): 217-220). In the ob mouse a single gene mutation (obese) results in profound obesity, which is accompanied by diabetes (Friedman J. M. et. al., (1991) Genomics 11: 1054-1062 ).

Therefore, the technical problem underlying the present invention was to provide for means and methods for modulating (pathological) metabolic conditions influencing body-weight regulation and/or energy homeostatic circuits. The solution to said technical problem is achieved by providing the embodiments characterized in the claims.

Accordingly, the present invention relates to genes with novel functions in body-weight regulation, energy homeostasis, metabolism, and obesity. The present invention discloses specific genes involved in the regulation of body-weight, energy homeostasis, metabolism, and obesity, as well as related diseases such as diabetes mellitus, eating disorder, cachexia, hypertension, coronary heart disease, hypercholesterolemia (dyslipidemia), and gallstones. In particular, the present invention describes the human

Pp2C1 homologous genes as being involved in those conditions mentioned above.

As shown in this invention magnesium-dependent protein phosphatase 1 D  
5 (PPM1D) is the human homolog of Drosophila protein phosphatase 2C  
(Pp2C1). The human wildtype p53-induced phosphatase 1 (Wip1; GenBank  
symbol PPM1D) gene encodes a type 2C protein phosphatase (PP2C) that  
is induced by ionizing radiation in a p53-dependent manner. The  
murine Wip1 mRNA is expressed ubiquitously in adult and embryonic  
10 tissues, though expression in the testis was much higher than in other  
tissues (Choi J. et al., (2000) Genomics 64(3):298-306). Mice deficient for  
the wild-type p53-induced phosphatase gene (Wip1) exhibit defects in  
reproductive organs, immune function, and cell cycle control (Choi J. et al.,  
(2002) Mol Cell Biol, 22:1094-1105). Inactivation of the p38 MAPK  
15 through PPM1D overexpression resulting from PPM1D amplification  
contributes to the development of human cancers by suppressing p53  
activation (Bulavin D. V. et al, (2002) Nat Genet 31(2):210-215).

So far, it has not been described that the proteins of the invention and  
20 homologous proteins are involved in the regulation of energy homeostasis  
and body-weight regulation and related disorders, and thus, no functions in  
metabolic diseases and dysfunctions and other diseases as listed above  
have been discussed.

25 In this invention we refer to the proteins encoded by Drosophila protein  
phosphatase 2C genes and homologous orthologs, preferably human and  
murine homologous polypeptides or proteins or nucleic acids encoding  
those proteins as proteins or nucleic acids of the invention.

30 The present invention discloses that protein phosphatase 2C homologous  
proteins are regulating the energy homeostasis and fat metabolism  
especially the metabolism and storage of triglycerides and glycogen, and

polynucleotides, which identify and encode the proteins disclosed in this invention. The invention also relates to vectors, host cells, antibodies, and recombinant methods for producing the polypeptides and polynucleotides of the invention. The invention also relates to the use of these  
5 polynucleotides, polypeptides and effectors thereof in the diagnosis, study, prevention, and treatment of metabolic diseases or dysfunctions, for example, but not limited to, metabolic syndrome including obesity, diabetes mellitus, eating disorder, cachexia, hypertension, coronary heart disease, hypercholesterolemia (dyslipidemia), and gallstones.

10

Protein phosphatase 2C homologous proteins and nucleic acid molecules coding therefore are obtainable from insect or vertebrate species, e.g. mammals or birds. Particularly preferred are nucleic acids encoding the human protein phosphatase 2C homologs (in particular the human isoforms  
15 of magnesium-dependent protein phosphatase 1D).

20

The invention particularly relates to a nucleic acid molecule encoding a polypeptide contributing to regulating the energy homeostasis and the metabolism of triglycerides and glycogen, wherein said nucleic acid molecule comprises

- (a) the nucleotide sequence of Drosophila protein phosphatase 2C, human protein phosphatase 2C homologs (in particular the human isoforms of magnesium-dependent protein phosphatase 1D), and/or a sequence complementary thereto,
- 25 (b) a nucleotide sequence which hybridizes at 50°C in a solution containing 1 x SSC and 0.1% SDS to a sequence of (a),
- (c) a sequence corresponding to the sequences of (a) or (b) within the degeneration of the genetic code,
- 30 (d) a sequence which encodes a polypeptide which is at least 85%, preferably at least 90%, more preferably at least 95%, more preferably at least 98% and up to 99,6% identical to the amino acid sequences of the protein phosphatase 2C protein, preferably of the



human protein phosphatase 2C homologs (in particular the human isoforms of magnesium-dependent protein phosphatase 1D),

(e) a sequence which differs from the nucleic acid molecule of (a) to (d) by mutation and wherein said mutation causes an alteration, deletion, duplication and/or premature stop in the encoded polypeptide or

(f) a partial sequence of any of the nucleotide sequences of (a) to (e) having a length of at least 15 bases, preferably at least 20 bases, more preferably at least 25 bases and most preferably at least 50 bases.

The present invention relates to genes with novel functions in body-weight regulation, energy homeostasis, metabolism, and obesity, fragments of said genes, polypeptides encoded by said genes or fragments thereof, and effectors e.g. antibodies, biologically active nucleic acids, such as antisense molecules or ribozymes, RNAi molecules, aptamers, peptides or low-molecular weight organic compounds recognizing said polynucleotides or polypeptides.

The ability to manipulate and screen the genomes of model organisms such as the fly *Drosophila melanogaster* provides a powerful tool to analyze biological and biochemical processes that have direct relevance to more complex vertebrate organisms due to significant evolutionary conservation of genes, cellular processes, and pathways (see, for example, Adams M. D. et al., (2000) *Science* 287: 2185-2195). Identification of novel gene functions in model organisms can directly contribute to the elucidation of correlative pathways in mammals (humans) and of methods of modulating them. A correlation between a pathology model (such as changes in triglyceride levels as indication for metabolic syndrome including obesity) and the modified expression of a fly gene can identify the association of the human ortholog with the particular human disease.

In one embodiment, a forward genetic screen is performed in fly displaying a mutant phenotype due to misexpression of a known gene (see, Johnston Nat Rev Genet 3: 176-188 (2002); Rorth P., (1996) Proc Natl Acad Sci U S A 93: 12418-12422). In this invention, we have used a genetic screen to identify mutations of protein phosphatase 2C homologous genes that cause changes in the body weight which is reflected by a significant change of triglyceride and glycogen levels. Triglycerides and glycogen levels reflect the status of energy storage in cells and are significantly increased in obese patients.

One resource for screening was a *Drosophila melanogaster* stock collection of EP-lines. The P-vector of this collection has Gal4-UAS-binding sites fused to a basal promoter that can transcribe adjacent genomic *Drosophila* sequences upon binding of Gal4 to UAS-sites (Brand & Perrimon (1993) Development 118:401-415; Rorth P., (1996) Proc Natl Acad Sci U S A 93:12418-12422). This enables the EP-line collection for overexpression of endogenous flanking gene sequences. In addition, without activation of the UAS-sites, integration of the EP-element into the gene is likely to cause a reduction of gene activity, and allows determining its function by evaluating the loss-of-function phenotype.

To isolate genes with a function in energy homeostasis, several thousand EP-lines were tested for their triglyceride/glycogen content after a prolonged feeding period (see Examples for more detail). Lines with significantly changed triglyceride/glycogen content were selected as positive candidates for further analysis. The change of triglyceride/glycogen content due to the loss of a gene function suggests gene activities in energy homeostasis in a dose dependent manner that control the amount of energy stored as triglycerides or glycogens.

In this invention, the content of triglycerides and glycogen of a pool of flies with the same genotype was analyzed after feeding for six days using a

triglyceride and a glycogen assay. Male flies hemizygous for the integration of vectors for *Drosophila* line HD-EP(X)10310 were analyzed in assays measuring the triglyceride and glycogen contents of these flies, illustrated in more detail in the EXAMPLES section. The results of the glycogen content analysis are shown in FIGURE 1.

Genomic DNA sequences were isolated that are localized to the EP vector (herein HD-EP(X)10310) integration. Using those isolated genomic sequences public databases like Berkeley *Drosophila* Genome Project (GadFly; see also FlyBase (1999) *Nucleic Acids Research* 27:85-88) were screened thereby identifying the integration site of the vectors, and the corresponding gene, described in more detail in the EXAMPLES section. The molecular organization of the gene is shown in FIGURE 2.

The invention also encompasses polynucleotides that encode the proteins of the invention and homologous proteins. Accordingly, any nucleic acid sequence, which encodes the amino acid sequences of the proteins of the invention and homologous proteins, can be used to generate recombinant molecules that express the proteins of the invention and homologous proteins. In a particular embodiment, the invention encompasses a nucleic acid encoding *Drosophila* protein phosphatase 2C or human protein phosphatase 2C homologs; referred to herein as the proteins of the invention. It will be appreciated by those skilled in the art that as a result of the degeneracy of the genetic code, a multitude of nucleotide sequences encoding the proteins, some bearing minimal homology to the nucleotide sequences of any known and naturally occurring gene, may be produced. The invention contemplates each and every possible variation of nucleotide sequence that can be made by selecting combinations based on possible codon choices.

Also encompassed by the invention are polynucleotide sequences that are capable of hybridizing to the claimed nucleotide sequences, and in

particular, those of the polynucleotide encoding the proteins of the invention, under various conditions of stringency. Hybridization conditions are based on the melting temperature ( $T_m$ ) of the nucleic acid binding complex or probe, as taught in Wahl & Berger (1987: Methods Enzymol. 152:399-407) and Kimmel (1987: Methods Enzymol. 152:507-511), and may be used at a defined stringency. Preferably, hybridization under stringent conditions means that after washing for 1 h with 1 x SSC and 0,1% SDS at 50°C, preferably at 55°C, more preferably at 62°C and most preferably at 65°C, particularly for 1h in 0.2 x SSC and 0.1% SDS at 50°C, preferably at 55°C, more preferably at 62°C and most preferably at 65°C, a positive hybridization signal is observed. Altered nucleic acid sequences encoding the proteins which are encompassed by the invention include deletions, insertions or substitutions of different nucleotides resulting in a polynucleotide that encodes the same or a functionally equivalent protein.

The encoded proteins may also contain deletions, insertions or substitutions of amino acid residues, which produce a silent change and result in functionally equivalent proteins. Deliberate amino acid substitutions may be made on the basis of similarity in polarity, charge, solubility, hydrophobicity, hydrophilicity, and/or the amphipathic nature of the residues as long as the biological activity of the protein is retained. Furthermore, the invention relates to peptide fragments of the proteins or derivatives thereof such as cyclic peptides, retro-inverso peptides or peptide mimetics having a length of at least 4, preferably at least 6 and up to 50 amino acids.

Also included within the scope of the present invention are alleles of the genes encoding the proteins of the invention and homologous proteins. As used herein, an 'allele' or 'allelic sequence' is an alternative form of the gene, which may result from at least one mutation in the nucleic acid sequence. Alleles may result in altered mRNAs or polypeptides whose

structures or function may or may not be altered. Any given gene may have none, one or many allelic forms. Common mutational changes, which give rise to alleles, are generally ascribed to natural deletions, additions or substitutions of nucleotides. Each of these types of changes may occur  
5 alone or in combination with the others, one or more times in a given sequence.

The nucleic acid sequences encoding the proteins of the invention and homologous proteins may be extended utilizing a partial nucleotide  
10 sequence and employing various methods known in the art to detect upstream sequences such as promoters and regulatory elements.

In order to express a biologically active protein, the nucleotide sequences encoding the proteins or functional equivalents, may be inserted into  
15 appropriate expression vectors, i.e., a vector which contains the necessary elements for the transcription and translation of the inserted coding sequence. Methods, which are well known to those skilled in the art, may be used to construct expression vectors containing sequences encoding the proteins and the appropriate transcriptional and translational control  
20 elements. Regulatory elements include for example a promoter, an initiation codon, a stop codon, a mRNA stability regulatory element, and a polyadenylation signal. Expression of a polynucleotide can be assured by (i) constitutive promoters such as the Cytomegalovirus (CMV) promoter/enhancer region, (ii) tissue specific promoters such as the insulin  
25 promoter (see, Soria et al., 2000, Diabetes 49:157), SOX2 gene promoter (see Li et al., 1998, Curr. Biol. 8:971-4), Msi-1 promoter (see Sakakibara et al., 1997, J. Neuroscience 17:8300-8312), alpha-cardia myosin heavy chain promoter or human atrial natriuretic factor promoter (Klug et al., 1996, J. clin. Invest 98:216-24; Wu et al., 1989, J. Biol. Chem.  
30 264:6472-79) or (iii) inducible promoters such as the tetracycline inducible system. Expression vectors can also contain a selection agent or marker gene that confers antibiotic resistance such as the neomycin, hygromycin

or puromycin resistance genes. These methods include in vitro recombinant DNA techniques, synthetic techniques, and in vivo genetic recombination. Such techniques are described in Sambrook, J. et al. (1989) *Molecular Cloning, A Laboratory Manual*, Cold Spring Harbor Press, Plainview, N.Y. and Ausubel, F.M. et al. (1989) *Current Protocols in Molecular Biology*, John Wiley & Sons, New York, N.Y.

In a further embodiment of the invention, natural, modified or recombinant nucleic acid sequences encoding the proteins of the invention and homologous proteins may be ligated to a heterologous sequence to encode a fusion protein.

A variety of expression vector/host systems may be utilized to contain and express sequences encoding the proteins or fusion proteins. These include, but are not limited to, micro-organisms such as bacteria transformed with recombinant bacteriophage, plasmid or cosmid DNA expression vectors; yeast transformed with yeast expression vectors; insect cell systems infected with virus expression vectors (e.g., baculovirus, adenovirus, adeno-associated virus, lentivirus, retrovirus); plant cell systems transformed with virus expression vectors (e.g., cauliflower mosaic virus, CaMV; tobacco mosaic virus, TMV) or with bacterial expression vectors (e.g., Ti or PBR322 plasmids); or animal cell systems.

The presence of polynucleotide sequences of the invention in a sample can be detected by DNA-DNA or DNA-RNA hybridization and/or amplification using probes or portions or fragments of said polynucleotides. Nucleic acid amplification based assays involve the use of oligonucleotides or oligomers based on the sequences specific for the gene to detect transformants containing DNA or RNA encoding the corresponding protein. As used herein 'oligonucleotides' or 'oligomers' refer to a nucleic acid sequence of at least about 10 nucleotides and as many as about 60 nucleotides,

preferably about 15 to 30 nucleotides, and more preferably about 20-25 nucleotides, which can be used as a probe or amplimer.

5 A wide variety of labels and conjugation techniques are known by those skilled in the art and may be used in various nucleic acid and amino acid assays. Means for producing labeled hybridization or PCR probes for detecting polynucleotide sequences include oligo-labeling, nick translation, end-labeling of labeled RNA probes, PCR amplification using a labeled nucleotide, or enzymatic synthesis. These procedures may be conducted  
10 using a variety of commercially available kits (Pharmacia & Upjohn, (Kalamazoo, Mich.); Promega (Madison Wis.); and U.S. Biochemical Corp., (Cleveland, Ohio).

The presence of proteins of the invention in a sample can be determined by  
15 immunological methods or activity measurement. A variety of protocols for detecting and measuring the expression of proteins, using either polyclonal or monoclonal antibodies specific for the protein or reagents for determining protein activity are known in the art. Examples include enzyme-linked immunosorbent assay (ELISA), radioimmunoassay (RIA), and  
20 fluorescence activated cell sorting (FACS). A two-site, monoclonal-based immunoassay utilizing monoclonal antibodies reactive to two non-interfering epitopes on the protein is preferred, but a competitive binding assay may be employed. These and other assays are described, among other places, in Hampton, R. et al. (1990; Serological Methods, a  
25 Laboratory Manual, APS Press, St Paul, Minn.) and Maddox, D. E. et al. (1983; J. Exp. Med. 158:1211-1216).

Suitable reporter molecules or labels, which may be used, include  
30 radionuclides, enzymes, fluorescent, chemiluminescent or chromogenic agents as well as substrates, co-factors, inhibitors, magnetic particles, and the like.

The nucleic acids encoding the proteins of the invention can be used to generate transgenic animal or site specific gene modifications in cell lines. Transgenic animals may be made through homologous recombination, where the normal locus of the genes encoding the proteins of the invention is altered. Alternatively, a nucleic acid construct is randomly integrated into the genome. Vectors for stable integration include plasmids, retroviruses and other animal viruses, YACs, and the like. The modified cells or animal are useful in the study of the function and regulation of the proteins of the invention. For example, a series of small deletions and/or substitutions may be made in the genes that encode the proteins of the invention to determine the role of particular domains of the protein, functions in pancreatic differentiation, etc.

Specific constructs of interest include anti-sense molecules, which will block the expression of the proteins of the invention, or expression of dominant negative mutations. A detectable marker, such as for example lac-Z, may be introduced in the locus of the genes of the invention, where upregulation of expression of the genes of the invention will result in an easily detected change in phenotype.

One may also provide for expression of the genes of the invention or variants thereof in cells or tissues where it is not normally expressed or at abnormal times of development. In addition, by providing expression of the proteins of the invention in cells in which they are not normally produced, one can induce changes in cell behavior.

DNA constructs for homologous recombination will comprise at least portions of the genes of the invention with the desired genetic modification, and will include regions of homology to the target locus. DNA constructs for random integration need not include regions of homology to mediate recombination. Conveniently, markers for positive and/or negative selection are included. Methods for generating cells having targeted gene



modifications through homologous recombination are known in the art. For embryonic stem (ES) cells, an ES cell line may be employed, or embryonic cells may be obtained freshly from a host, e.g. mouse, rat, guinea pig etc. Such cells are grown on an appropriate fibroblast-feeder layer or grown in  
5 presence of leukemia inhibiting factor (LIF).

When ES or embryonic cells or somatic pluripotent stem cells have been transformed, they may be used to produce transgenic animals. After transformation, the cells are plated onto a feeder layer in an appropriate  
10 medium. Cells containing the construct may be detected by employing a selective medium. After sufficient time for colonies to grow, they are picked and analyzed for the occurrence of homologous recombination or integration of the construct. Those colonies that are positive may then be used for embryo manipulation and blastocyst injection. Blastocysts are  
15 obtained from 4 to 6 week old superovulated females. The ES cells are trypsinized, and the modified cells are injected into the blastocoel of the blastocyst. After injection, the blastocysts are returned to each uterine horn of pseudopregnant females. Females are then allowed to go to term and the resulting offspring screened for the construct. By providing for a  
20 different phenotype of the blastocyst and the genetically modified cells, chimeric progeny can be readily detected. The chimeric animals are screened for the presence of the modified gene and males and females having the modification are mated to produce homozygous progeny. If the gene alterations cause lethality at some point in development, tissues or  
25 organs can be maintained as allogenic or congenic grafts or transplants, or in vitro culture. The transgenic animals may be any non-human mammal, such as laboratory animal, domestic animals, etc. The transgenic animals may be used in functional studies, drug screening, etc.

## Diagnostics and Therapeutics

The data disclosed in this invention show that the nucleic acids and proteins of the invention and effector molecules thereof are useful in diagnostic and therapeutic applications implicated, for example, but not limited to, metabolic syndrome including obesity, diabetes mellitus, eating disorder, cachexia, hypertension, coronary heart disease, hypercholesterolemia (dyslipidemia), and gallstones. Hence, diagnostic and therapeutic uses for the proteins of the invention nucleic acids and proteins of the invention are, for example but not limited to, the following: (i) protein therapeutic, (ii) small molecule drug target, (iii) antibody target (therapeutic, diagnostic, drug targeting/cytotoxic antibody), (iv) diagnostic and/or prognostic marker, (v) gene therapy (gene delivery/gene ablation), (vi) research tools, and (vii) tissue regeneration in vitro and in vivo (regeneration for all these tissues and cell types composing these tissues and cell types derived from these tissues).

The nucleic acids and proteins of the invention and effectors thereof are useful in diagnostic and therapeutic applications implicated in various applications as described below. For example, but not limited to, cDNAs encoding the proteins of the invention and particularly their human homologues may be useful in gene therapy, and the proteins of the invention and particularly their human homologues may be useful when administered to a subject in need thereof. By way of non-limiting example, the compositions of the present invention will have efficacy for treatment of patients suffering from, for example, but not limited to, in metabolic disorders as described above.

The nucleic acids of the invention or fragments thereof, may further be useful in diagnostic applications, wherein the presence or amount of the nucleic acids or the proteins are to be assessed. Further antibodies that

bind immunospecifically to the substances of the invention may be used in therapeutic or diagnostic methods.

5 For example, in one aspect, antibodies, which are specific for the proteins of the invention and homologous proteins, may be used directly as an effector, e.g. an antagonist or indirectly as a targeting or delivery mechanism for bringing a pharmaceutical agent to cells or tissue which express the protein. The antibodies may be generated using methods that are well known in the art. Such antibodies may include, but are not limited to, polyclonal, monoclonal, chimeric single chain, Fab fragments, and  
10 fragments produced by a Fab expression library. Neutralising antibodies, (i.e., those which inhibit dimer formation) are especially preferred for therapeutic use.

15 For the production of antibodies, various hosts including goats, rabbits, rats, mice, humans, and others, may be immunized by injection with the protein or any fragment or oligopeptide thereof which has immunogenic properties. Depending on the host species, various adjuvants may be used to increase immunological response. It is preferred that the peptides,  
20 fragments or oligopeptides used to induce antibodies to the protein have an amino acid sequence consisting of at least five amino acids, and more preferably at least 10 amino acids.

Monoclonal antibodies to the proteins may be prepared using any  
25 technique that provides for the production of antibody molecules by continuous cell lines in culture. These include, but are not limited to, the hybridoma technique, the human B-cell hybridoma technique, and the EBV-hybridoma technique (Köhler, G. et al. (1975) Nature 256:495-497; Kozbor, D. et al. (1985) J. Immunol. Methods 81:31-42; Cote, R. J. et al.  
30 Proc. Natl. Acad. Sci. 80:2026-2030; Cole, S. P. et al. (1984) Mol. Cell Biol. 62:109-120).

In addition, techniques developed for the production of 'chimeric antibodies', the splicing of mouse antibody genes to human antibody genes to obtain a molecule with appropriate antigen specificity and biological activity can be used (Morrison, S. L. et al. (1984) Proc. Natl. Acad. Sci. 81:6851-6855; Neuberger, M. S. et al (1984) Nature 312:604-608; Takeda, S. et al. (1985) Nature 314:452-454). Alternatively, techniques described for the production of single chain antibodies may be adapted, using methods known in the art, to produce single chain antibodies specific for the proteins of the invention and homologous proteins. Antibodies with related specificity, but of distinct idiotypic composition, may be generated by chain shuffling from random combinatorial immunoglobulin libraries (Burton, D. R. (1991) Proc. Natl. Acad. Sci. 88:11120-3). Antibodies may also be produced by inducing in vivo production in the lymphocyte population or by screening recombinant immunoglobulin libraries or panels of highly specific binding reagents as disclosed in the literature (Orlandi, R. et al. (1989) Proc. Natl. Acad. Sci. 86:3833-3837; Winter, G. et al. (1991) Nature 349:293-299).

Antibody fragments which contain specific binding sites for the proteins may also be generated. For example, such fragments include, but are not limited to, the  $F(ab')_2$  fragments which can be produced by Pepsin digestion of the antibody molecule and the Fab fragments which can be generated by reducing the disulfide bridges of  $F(ab')_2$  fragments. Alternatively, Fab expression libraries may be constructed to allow rapid and easy identification of monoclonal Fab fragments with the desired specificity (Huse, W. D. et al. (1989) Science 254:1275-1281).

Various immunoassays may be used for screening to identify antibodies having the desired specificity. Numerous protocols for competitive binding and immunoradiometric assays using either polyclonal or monoclonal antibodies with established specificities are well known in the art. Such immunoassays typically involve the measurement of complex formation

between the protein and its specific antibody. A two-site, monoclonal-based immunoassay utilizing monoclonal antibodies reactive to two non-interfering protein epitopes are preferred, but a competitive binding assay may also be employed (Maddox, supra).

5

In another embodiment of the invention, the polynucleotides or fragments thereof or nucleic acid effector molecules such as antisense molecules, aptamers, RNAi molecules or ribozymes may be used for therapeutic purposes. In one aspect, aptamers, i.e. nucleic acid molecules, which are capable of binding to a protein of the invention and modulating its activity, may be generated by a screening and selection procedure involving the use of combinatorial nucleic acid libraries.

10

In a further aspect, antisense molecules may be used in situations in which it would be desirable to block the transcription of the mRNA. In particular, cells may be transformed with sequences complementary to polynucleotides encoding the proteins of the invention and homologous proteins. Thus, antisense molecules may be used to modulate protein activity or to achieve regulation of gene function. Such technology is now well known in the art, and sense or antisense oligomers or larger fragments, can be designed from various locations along the coding or control regions of sequences encoding the proteins. Expression vectors derived from retroviruses, adenovirus, herpes or vaccinia viruses or from various bacterial plasmids may be used for delivery of nucleotide sequences to the targeted organ, tissue or cell population. Methods, which are well known to those skilled in the art, can be used to construct recombinant vectors, which will express antisense molecules complementary to the polynucleotides of the genes encoding the proteins of the invention and homologous proteins. These techniques are described both in Sambrook et al. (supra) and in Ausubel et al. (supra). Genes encoding the proteins of the invention and homologous proteins can be turned off by transforming a cell or tissue with expression vectors, which

15

20

25

30

express high levels of polynucleotides that encode the proteins of the invention and homologous proteins or fragments thereof. Such constructs may be used to introduce untranslatable sense or antisense sequences into a cell. Even in the absence of integration into the DNA, such vectors may  
5 continue to transcribe RNA molecules until they are disabled by endogenous nucleases. Transient expression may last for a month or more with a non-replicating vector and even longer if appropriate replication elements are part of the vector system.

10 As mentioned above, modifications of gene expression can be obtained by designing antisense molecules, e.g. DNA, RNA or nucleic acid analogues such as PNA, to the control regions of the genes encoding the proteins of the invention and homologous proteins, i.e., the promoters, enhancers, and introns. Oligonucleotides derived from the transcription initiation site, e.g.,  
15 between positions -10 and +10 from the start site, are preferred. Similarly, inhibition can be achieved using "triple helix" base-pairing methodology. Triple helix pairing is useful because it cause inhibition of the ability of the double helix to open sufficiently for the binding of polymerases, transcription factors or regulatory molecules. Recent therapeutic advances  
20 using triplex DNA have been described in the literature (Gee, J. E. et al. (1994) In; Huber, B. E. and B. I. Carr, Molecular and Immunologic Approaches, Futura Publishing Co., Mt. Kisco, N.Y.). The antisense molecules may also be designed to block translation of mRNA by preventing the transcript from binding to ribosomes.

25

Ribozymes, enzymatic RNA molecules, may also be used to catalyze the specific cleavage of RNA. The mechanism of ribozyme action involves sequence-specific hybridization of the ribozyme molecule to complementary target RNA, followed by endonucleolytic cleavage. Examples, which may  
30 be used, include engineered hammerhead motif ribozyme molecules that can be specifically and efficiently catalyze endonucleolytic cleavage of sequences encoding the proteins of the invention and homologous

proteins. Specific ribozyme cleavage sites within any potential RNA target are initially identified by scanning the target molecule for ribozyme cleavage sites which include the following sequences: GUA, GUU, and GUC. Once identified, short RNA sequences of between 15 and 20 ribonucleotides corresponding to the region of the target gene containing the cleavage site may be evaluated for secondary structural features which may render the oligonucleotide inoperable. The suitability of candidate targets may also be evaluated by testing accessibility to hybridization with complementary oligonucleotides using ribonuclease protection assays.

Nucleic acid effector molecules, e.g. antisense molecules and ribozymes of the invention may be prepared by any method known in the art for the synthesis of nucleic acid molecules. These include techniques for chemically synthesizing oligonucleotides such as solid phase phosphoramidite chemical synthesis. Alternatively, RNA molecules may be generated by in vitro and in vivo transcription of DNA sequences. Such DNA sequences may be incorporated into a variety of vectors with suitable RNA polymerase promoters such as T7 or SP6. Alternatively, these cDNA constructs that synthesize antisense RNA constitutively or inducibly can be introduced into cell lines, cells or tissues. RNA molecules may be modified to increase intracellular stability and half-life. Possible modifications include, but are not limited to, the addition of flanking sequences at the 5' and/or 3' ends of the molecule or modifications in the nucleobase, sugar and/or phosphate moieties, e.g. the use of phosphorothioate or 2' O-methyl rather than phosphodiesterase linkages within the backbone of the molecule. This concept is inherent in the production of PNAs and can be extended in all of these molecules by the inclusion of non-traditional bases such as inosine, queosine, and wybutosine, as well as acetyl-, methyl-, thio-, and similarly modified forms of adenine, cytidine, guanine, thymine, and uridine which are not as easily recognized by endogenous endonucleases.

Many methods for introducing vectors into cells or tissues are available and equally suitable for use in vivo, in vitro, and ex vivo. For ex vivo therapy, vectors may be introduced into stem cells taken from the patient and clonally propagated for autologous transplant back into that same patient. Delivery by transfection and by liposome injections may be achieved using methods, which are well known in the art. Any of the therapeutic methods described above may be applied to any suitable subject including, for example, mammals such as dogs, cats, cows, horses, rabbits, monkeys, and most preferably, humans.

An additional embodiment of the invention relates to the administration of a pharmaceutical composition, in conjunction with a pharmaceutically acceptable carrier, for any of the therapeutic effects discussed above. Such pharmaceutical compositions may consist of the nucleic acids and the proteins of the invention and homologous nucleic acids or proteins, antibodies to the proteins of the invention and homologous proteins, mimetics, agonists, antagonists or inhibitors of the proteins of the invention and homologous proteins or nucleic acids. The compositions may be administered alone or in combination with at least one other agent, such as stabilizing compound, which may be administered in any sterile, biocompatible pharmaceutical carrier, including, but not limited to, saline, buffered saline, dextrose, and water. The compositions may be administered to a patient alone or in combination with other agents, drugs or hormones. The pharmaceutical compositions utilized in this invention may be administered by any number of routes including, but not limited to, oral, intravenous, intramuscular, intra-arterial, intramedullary, intrathecal, intraventricular, transdermal, subcutaneous, intraperitoneal, intranasal, enteral, topical, sublingual or rectal means.

In addition to the active ingredients, these pharmaceutical compositions may contain suitable pharmaceutically-acceptable carriers comprising excipients and auxiliaries, which facilitate processing of the active



compounds into preparations, which can be used pharmaceutically. Further details on techniques for formulation and administration may be found in the latest edition of Remington's Pharmaceutical Sciences (Maack Publishing Co., Easton, Pa.).

5

Pharmaceutical compositions suitable for use in the invention include compositions wherein the active ingredients are contained in an effective amount to achieve the intended purpose. The determination of an effective dose is well within the capability of those skilled in the art. For any compounds, the therapeutically effective dose can be estimated initially either in cell culture assays, e.g., of preadipocyte cell lines or in animal models, usually mice, rabbits, dogs or pigs. The animal model may also be used to determine the appropriate concentration range and route of administration. Such information can then be used to determine useful doses and routes for administration in humans. A therapeutically effective dose refers to that amount of active ingredient, for example the nucleic acids or the proteins of the invention or fragments thereof or antibodies, which is sufficient for treating a specific condition. Therapeutic efficacy and toxicity may be determined by standard pharmaceutical procedures in cell cultures or experimental animals, e.g., ED50 (the dose therapeutically effective in 50% of the population) and LD50 (the dose lethal to 50% of the population). The dose ratio between therapeutic and toxic effects is the therapeutic index, and it can be expressed as the ratio, LD50/ED50. Pharmaceutical compositions, which exhibit large therapeutic indices, are preferred. The data obtained from cell culture assays and animal studies is used in formulating a range of dosage for human use. The dosage contained in such compositions is preferably within a range of circulating concentrations that include the ED50 with little or no toxicity. The dosage varies within this range depending upon the dosage form employed, sensitivity of the patient, and the route of administration. The exact dosage will be determined by the practitioner, in light of factors related to the subject that requires treatment. Dosage and administration are adjusted to

10  
15  
20  
25  
30

provide sufficient levels of the active moiety or to maintain the desired effect. Factors, which may be taken into account, include the severity of the disease state, general health of the subject, age, weight, and gender of the subject, diet, time and frequency of administration, drug combination(s), reaction sensitivities, and tolerance/response to therapy. Long-acting pharmaceutical compositions may be administered every 3 to 4 days, every week or once every two weeks depending on half-life and clearance rate of the particular formulation. Normal dosage amounts may vary from 0.1 to 100,000 microg, up to a total dose of about 1 g, depending upon the route of administration. Guidance as to particular dosages and methods of delivery is provided in the literature and generally available to practitioners in the art. Those skilled in the art employ different formulations for nucleotides than for proteins or their inhibitors. Similarly, delivery of polynucleotides or polypeptides will be specific to particular cells, conditions, locations, etc.

In another embodiment, antibodies which specifically bind to the proteins may be used for the diagnosis of conditions or diseases characterized by or associated with over- or underexpression of the proteins of the invention and homologous proteins or in assays to monitor patients being treated with the proteins of the invention and homologous proteins, or effectors thereof, e.g. agonists, antagonists, or inhibitors. Diagnostic assays include methods which utilize the antibody and a label to detect the protein in human body fluids or extracts of cells or tissues. The antibodies may be used with or without modification, and may be labeled by joining them, either covalently or non-covalently, with a reporter molecule. A wide variety of reporter molecules which are known in the art may be used several of which are described above.

A variety of protocols including ELISA, RIA, and FACS for measuring proteins are known in the art and provide a basis for diagnosing altered or abnormal levels of gene expression. Normal or standard values for gene

expression are established by combining body fluids or cell extracts taken from normal mammalian subjects, preferably human, with antibodies to the protein under conditions suitable for complex formation. The amount of standard complex formation may be quantified by various methods, but preferably by photometric means. Quantities of protein expressed in control and disease, samples e.g. from biopsied tissues are compared with the standard values. Deviation between standard and subject values establishes the parameters for diagnosing disease.

10 In another embodiment of the invention, the polynucleotides specific for the proteins of the invention and homologous proteins may be used for diagnostic purposes. The polynucleotides, which may be used, include oligonucleotide sequences, antisense RNA and DNA molecules, and PNAs. The polynucleotides may be used to detect and quantitate gene expression  
15 in biopsied tissues in which gene expression may be correlated with disease. The diagnostic assay may be used to distinguish between absence, presence, and excess gene expression, and to monitor regulation of protein levels during therapeutic intervention.

20 In one aspect, hybridization with probes which are capable of detecting polynucleotide sequences, including genomic sequences, encoding the proteins of the invention and homologous proteins or closely related molecules, may be used to identify nucleic acid sequences which encode the respective protein. The hybridization probes of the subject invention  
25 may be DNA or RNA and are preferably derived from the nucleotide sequence of the polynucleotide encoding the proteins of the invention or from a genomic sequence including promoter, enhancer elements, and introns of the naturally occurring gene. Hybridization probes may be labeled by a variety of reporter groups, for example, radionuclides such as  $^{32}\text{P}$  or  
30  $^{35}\text{S}$  or enzymatic labels, such as alkaline phosphatase coupled to the probe via avidin/biotin coupling systems, and the like.

Polynucleotide sequences specific for the proteins of the invention and homologous nucleic acids may be used for the diagnosis of conditions or diseases, which are associated with the expression of the proteins. Examples of such conditions or diseases include, but are not limited to, 5 pancreatic diseases and disorders, including diabetes. Polynucleotide sequences specific for the proteins of the invention and homologous proteins may also be used to monitor the progress of patients receiving treatment for pancreatic diseases and disorders, including diabetes. The polynucleotide sequences may be used qualitative or quantitative assays, 10 e.g. in Southern or Northern analysis, dot blot or other membrane-based technologies; in PCR technologies; or in dip stick, pin, ELISA or chip assays utilizing fluids or tissues from patient biopsies to detect altered gene expression.

15 In a particular aspect, the nucleotide sequences specific for the proteins of the invention and homologous nucleic acids may be useful in assays that detect activation or induction of various metabolic diseases or dysfunctions, for example, obesity, diabetes mellitus, eating disorder, cachexia, hypertension, coronary heart disease, hypercholesterolemia 20 (dyslipidemia), and gallstones. The nucleotide sequences may be labeled by standard methods, and added to a fluid or tissue sample from a patient under conditions suitable for the formation of hybridization complexes. After a suitable incubation period, the sample is washed and the signal is quantitated and compared with a standard value. If the amount of signal in 25 the biopsied or extracted sample is significantly altered from that of a comparable have hybridized with nucleotide sequences in the sample, and the presence of altered levels of nucleotide sequences encoding the proteins of the invention and homologous proteins in the sample indicates the presence of the associated disease. Such assays may also be used to 30 evaluate the efficacy of a particular therapeutic treatment regimen in animal studies, in clinical trials or in monitoring the treatment of an individual patient.

In order to provide a basis for the diagnosis of a disease associated with expression of the proteins of the invention and homologous proteins, a normal or standard profile for expression is established. This may be accomplished by combining body fluids or cell extracts taken from normal subjects, either animal or human, with a sequence or a fragment thereof, which is specific for the nucleic acids encoding the proteins of the invention and homologous nucleic acids, under conditions suitable for hybridization or amplification. Standard hybridization may be quantified by comparing the values obtained from normal subjects with those from an experiment where a known amount of a substantially purified polynucleotide is used. Standard values obtained from normal samples may be compared with values obtained from samples from patients who are symptomatic for disease. Deviation between standard and subject values is used to establish the presence of disease. Once disease is established and a treatment protocol is initiated, hybridization assays may be repeated on a regular basis to evaluate whether the level of expression in the patient begins to approximate that, which is observed in the normal patient. The results obtained from successive assays may be used to show the efficacy of treatment over a period ranging from several days to months.

With respect to metabolic diseases such as described above the presence of an unusual amount of transcript in biopsied tissue from an individual may indicate a predisposition for the development of the disease or may provide a means for detecting the disease prior to the appearance of actual clinical symptoms. A more definitive diagnosis of this type may allow health professionals to employ preventative measures or aggressive treatment earlier thereby preventing the development or further progression of the metabolic diseases and disorders.

Additional diagnostic uses for oligonucleotides designed from the sequences encoding the proteins of the invention and homologous proteins may involve the use of PCR. Such oligomers may be chemically

synthesized, generated enzymatically or produced from a recombinant source. Oligomers will preferably consist of two nucleotide sequences, one with sense orientation (5prime.fwdarw.3prime) and another with antisense (3prime.rarw.5prime), employed under optimized conditions for identification of a specific gene or condition. The same two oligomers, nested sets of oligomers or even a degenerate pool of oligomers may be employed under less stringent conditions for detection and/or quantification of closely related DNA or RNA sequences.

10 In another embodiment of the invention, the nucleic acid sequences may also be used to generate hybridization probes, which are useful for mapping the naturally occurring genomic sequence. The sequences may be mapped to a particular chromosome or to a specific region of the chromosome using well known techniques. Such techniques include FISH, 15 FACS or artificial chromosome constructions, such as yeast artificial chromosomes, bacterial artificial chromosomes, bacterial P1 constructions or single chromosome cDNA libraries as reviewed in Price, C. M. (1993) Blood Rev. 7:127-134, and Trask, B. J. (1991) Trends Genet. 7:149-154. FISH (as described in Verma et al. (1988) Human Chromosomes: A Manual 20 of Basic Techniques, Pergamon Press, New York, N.Y.). The results may be correlated with other physical chromosome mapping techniques and genetic map data. Examples of genetic map data can be found in the 1994 Genome Issue of Science (265:1981f). Correlation between the location of the gene encoding the proteins of the invention on a physical chromosomal 25 map and a specific disease or predisposition to a specific disease, may help to delimit the region of DNA associated with that genetic disease.

The nucleotide sequences of the subject invention may be used to detect differences in gene sequences between normal, carrier or affected 30 individuals. An analysis of polymorphisms, e.g. single nucleotide polymorphisms may be carried out. Further, in situ hybridization of chromosomal preparations and physical mapping techniques such as

linkage analysis using established chromosomal markers may be used for extending genetic maps. Often the placement of a gene on the chromosome of another mammalian species, such as mouse, may reveal associated markers even if the number or arm of a particular human  
5 chromosome is not known. New sequences can be assigned to chromosomal arms or parts thereof, by physical mapping. This provides valuable information to investigators searching for disease genes using positional cloning or other gene discovery techniques. Once the disease or syndrome has been crudely localized by genetic linkage to a particular  
10 genomic region, for example, AT to 11q22-23 (Gatti, R. A. et al. (1988) Nature 336:577-580), any sequences mapping to that area may represent associated or regulatory genes for further investigation. The nucleotide sequences of the subject invention may also be used to detect differences in the chromosomal location due to translocation, inversion, etc. among  
15 normal, carrier or affected individuals.

In another embodiment of the invention, the proteins of the invention, their catalytic or immunogenic fragments or oligopeptides thereof, an in vitro model, a genetically altered cell or animal, can be used for screening  
20 libraries of compounds in any of a variety of drug screening techniques. One can identify effectors, e.g. receptors, enzymes, proteins, ligands, or substrates that bind to, modulate or mimic the action of one or more of the proteins of the invention. The protein or fragment thereof employed in such screening may be free in solution, affixed to a solid support, borne on a cell  
25 surface, or located intracellularly. The formation of binding complexes, between the proteins of the invention and the agent tested, may be measured. Agents could also, either directly or indirectly, influence the activity of the proteins of the invention. For example the phosphatase activity of the proteins of the invention could be measured in vitro by using  
30 recombinantly expressed and purified protein phosphatase 2C or fragments thereof by making use of artificial substrates well known in the art, i.e. but not exclusively DiFMUP (Molecular Probes, Eugene, Oregon), which are

converted to fluorophores or chromophores upon dephosphorylation. Alternatively, the dephosphorylation of physiological substrates of the phosphatases could be measured by making use of any of the well known screening technologies suitable for the detection of the phosphorylation status of their physiological substrates. For example, but not exclusively, the phosphorylation status of peptides derived from their physiological substrates can be monitored by binding of phospho-side specific antibodies resulting in an increase of the polarization of the complex.

10 In addition activity of protein phosphatase 2C against its physiological substrate(s) or derivatives thereof could be measured in cell-based assays. Agents may also interfere with posttranslational modifications of the protein, such as phosphorylation and dephosphorylation, farnesylation, palmitoylation, acetylation, alkylation, ubiquitination, proteolytic  
15 processing, subcellular localization and degradation. Moreover, agents could influence the dimerization or oligomerization of the proteins of the invention or, in a heterologous manner, of the proteins of the invention with other proteins, for example, but not exclusively, docking proteins, enzymes, receptors, or translation factors. Agents could also act on the  
20 physical interaction of the proteins of this invention with other proteins, which are required for protein function, for example, but not exclusively, their downstream signaling.

Methods for determining protein-protein interaction are well known in the art. For example binding of a fluorescently labeled peptide derived from the  
25 interacting protein to the protein of the invention, or vice versa, could be detected by a change in polarisation. In case that both binding partners, which can be either the full length proteins as well as one binding partner as the full length protein and the other just represented as a peptide are  
30 fluorescently labeled, binding could be detected by fluorescence energy transfer (FRET) from one fluorophore to the other. In addition, a variety of commercially available assay principles suitable for detection of



protein-protein interaction are well known in the art, for example but not exclusively AlphaScreen (PerkinElmer) or Scintillation Proximity Assays (SPA) by Amersham. Alternatively, the interaction of the proteins of the invention with cellular proteins could be the basis for a cell-based screening assay, in which both proteins are fluorescently labeled and interaction of both proteins is detected by analysing cotranslocation of both proteins with a cellular imaging reader, as has been developed for example, but not exclusively, by Cellomics or EvotecOAI. In all cases the two or more binding partners can be different proteins with one being the protein of the invention, or in case of dimerization and/or oligomerization the protein of the invention itself. Proteins of the invention, for which one target mechanism of interest, but not the only one, would be such protein/protein interactions are protein phosphatase 2C.

Of particular interest are screening assays for agents that have a low toxicity for mammalian cells. The term "agent" as used herein describes any molecule, e.g. protein or pharmaceutical, with the capability of altering or mimicking the physiological function of one or more of the proteins of the invention. Candidate agents encompass numerous chemical classes, though typically they are organic molecules, preferably small organic compounds having a molecular weight of more than 50 and less than about 2,500 Daltons. Candidate agents comprise functional groups necessary for structural interaction with proteins, particularly hydrogen bonding, and typically include at least an amine, carbonyl, hydroxyl or carboxyl group, preferably at least two of the functional chemical groups. The candidate agents often comprise carbocyclic or heterocyclic structures and/or aromatic or polyaromatic structures substituted with one or more of the above functional groups.

Candidate agents are also found among biomolecules including peptides, saccharides, fatty acids, steroids, purines, pyrimidines, nucleic acids and derivatives, structural analogs or combinations thereof. Candidate agents

are obtained from a wide variety of sources including libraries of synthetic or natural compounds. For example, numerous means are available for random and directed synthesis of a wide variety of organic compounds and biomolecules, including expression of randomized oligonucleotides and oligopeptides. Alternatively, libraries of natural compounds in the form of bacterial, fungal, plant and animal extracts are available or readily produced. Additionally, natural or synthetically produced libraries and compounds are readily modified through conventional chemical, physical and biochemical means, and may be used to produce combinatorial libraries. Known pharmacological agents may be subjected to directed or random chemical modifications, such as acylation, alkylation, esterification, amidification, etc. to produce structural analogs. Where the screening assay is a binding assay, one or more of the molecules may be joined to a label, where the label can directly or indirectly provide a detectable signal.

Another technique for drug screening, which may be used, provides for high throughput screening of compounds having suitable binding affinity to the protein of interest as described in published PCT application WO84/03564. In this method, as applied to the proteins of the invention large numbers of different small test compounds, e.g. aptamers, peptides, low-molecular weight compounds etc., are provided or synthesized on a solid substrate, such as plastic pins or some other surface. The test compounds are reacted with the proteins or fragments thereof, and washed. Bound proteins are then detected by methods well known in the art. Purified proteins can also be coated directly onto plates for use in the aforementioned drug screening techniques. Alternatively, non-neutralizing antibodies can be used to capture the peptide and immobilize it on a solid support. In another embodiment, one may use competitive drug screening assays in which neutralizing antibodies capable of binding the protein specifically compete with a test compound for binding the protein. In this manner, the antibodies can be used to detect the presence of any peptide, which shares one or more antigenic determinants with the protein.

Finally, the invention also relates to a kit comprising at least one of

- (a) a protein phosphatase 2C nucleic acid molecule or a fragment thereof;
- (b) a protein phosphatase 2C amino acid molecule or a fragment or an isoform thereof;
- (c) a vector comprising the nucleic acid of (a);
- (d) a host cell comprising the nucleic acid of (a) or the vector of (b);
- (e) a polypeptide encoded by the nucleic acid of (a);
- (f) a fusion polypeptide encoded by the nucleic acid of (a);
- (g) an antibody, an aptamer or another effector against the nucleic acid of (a) or the polypeptide of (b), (e) or (f) and
- (h) an anti-sense oligonucleotide of the nucleic acid of (a).

The kit may be used for diagnostic or therapeutic purposes or for screening applications as described above. The kit may further contain user instructions.

The Figures show:

FIGURE 1 shows the content of energy storage glycogen of *Drosophila* Pp2C1 (GadFly Accession Number CG8127) mutants. Shown is the change of glycogen content of HD-EP(X)10310 flies caused by integration of the P-vector into the annotated transcription unit (columns 2 and 4) in comparison to controls containing about 20 fly lines of the proprietary EP collection ('HD-control (70°C)'), column 1, 'HD-control (90°C)'), column 3).

FIGURE 2 shows the molecular organization of the mutated Pp2C1 (GadFly Accession Number CG2984) gene locus.

FIGURE 3 shows the nucleic acid and amino acid sequences of the human magnesium-dependent protein phosphatase 1D (PPM1D).

Figure 3A shows the nucleic acid sequence of human PPM1D (SEQ ID NO: 1).

Figure 3B shows the amino acid sequence (one-letter code) of human PPM1D (SEQ ID NO: 2).

5

The examples illustrate the invention:

10 Example 1: Measurement of energy storage metabolites (ESM) contents in *Drosophila*

Mutant flies are obtained from a fly mutation stock collection. The flies are grown under standard conditions known to those skilled in the art. In the course of the experiment, additional feedings with bakers yeast (*Saccharomyces cerevisiae*) are provided for the EP-line HD-EP(X)10310. The average change of triglyceride and glycogen (herein referred to as energy storage metabolites, ESM) content of *Drosophila* containing the EP-vector as hemizygous viable integration was investigated in comparison to control flies, respectively (see FIGURE 1). For determination of ESM content, flies were incubated for 5 min at 70°C or 90°C in an aqueous buffer using a waterbath, followed by hot extraction. After another 5 min incubation at 70°C or 90°C and mild centrifugation, the triglyceride content of the flies extract was determined using Sigma Triglyceride (INT 336-10 or -20) assay by measuring changes in the optical density according to the manufacturer's protocol, and the glycogen content of the flies extract was determined using Roche (Starch UV-method Cat. No. 0207748) assay by measuring changes in the optical density according to the manufacturer's protocol. As a reference the protein content of the same extract was measured using BIO-RAD DC Protein Assay according to the manufacturer's protocol. These experiments and assays were repeated several times.

15  
20  
25  
30

The average glycogen level ( $\mu\text{g}$  glycogen/ $\mu\text{g}$  protein) of 19 fly lines of the proprietary EP-collection with X-chromosomal insertions, determined at 70°C (referred to as 'HD-control (70°C)') is shown as 100% in the first column in FIGURE 1. The average glycogen level (microg glycogen/microg protein) of 20 fly lines of the proprietary EP-collection with X-chromosomal insertions, determined at 90°C (referred to as 'HD-control (90°C)') is shown as 100% in the third column in FIGURE 1. Standard deviations of the measurements are shown as thin bars.

HD-EP(X)10310 hemizygous flies show constantly a slightly higher triglyceride content ( $\mu\text{g}$  triglyceride/ $\mu\text{g}$  protein) than the controls (data not shown). HD-EP(X)10310 hemizygous flies also show constantly a higher glycogen content ( $\mu\text{g}$  glycogen/ $\mu\text{g}$  protein) than the controls, determined at different temperature (column 2 in FIGURE 1, 'HD-10310 (70°C)' and column 4 in FIGURE 1, 'HD-10310 (90°C)'). Therefore, the loss of gene activity is responsible for changes in the metabolism of the energy storage metabolites.

#### Example 2: Identification of a Drosophila gene responsible for a change in glycogen and triglyceride contents

Genomic DNA sequences were isolated that are localized directly adjacent to the EP vector (herein HD-EP(X)10310) integration. Using those isolated genomic sequences public databases like Berkeley Drosophila Genome Project (GadFly) were screened thereby confirming the hemizygous viable integration site of the HD-EP(X)10310 vector into an intron of Pp2C1 in antisense orientation. FIGURE 2 shows the molecular organization of this gene locus. The chromosomal localization site of integration of the vector of HD-EP(X)10310 is at gene locus X, 4D1 (according to Flybase) or X, 4C8 (according to Gadfly release 2). In FIGURE 2, genomic DNA sequence is represented by the assembly as a dotted grey line in middle of the figure

that includes the integration site of HD-EP(X)10310. Numbers represent the coordinates of the genomic DNA (starting at position 4489000 on chromosome X, ending at position 4497000 on chromosome X). The insertion site of the P-element in Drosophila line HD-EP(X)10310 is shown as bar in the "P. Elements +" line and is labeled. Dark grey bars on the "cDNA -" line, partly linked by light grey bars, represent the predicted genes (as predicted by the Berkeley Drosophila Genome Project, GadFly and by Magpie). Predicted exons are shown as dark grey bars, predicted introns are shown as light grey bars. The gene Pp2C1 (Gadfly Accession Number CG2984) is labeled. Transcribed DNA sequences (ESTs) are shown as grey bars in the "EST +" and "EST -" lines. Therefore, expression of the cDNA encoding Pp2C1 could be affected by integration of the vector of line HD-EP(X)10310, leading to a change in the amount of energy storage metabolites.

Table 1 is summarizing the data of our molecular analysis of the Drosophila protein identified in this invention as being involved in the regulation of the metabolism.

Table 1. Molecular analysis of Drosophila protein phosphatase 2C

<b>Analysis</b>	<b>Protein phosphatase 2C (Pp2C1)</b>
<b>Genetic interaction:</b>	not described (Flybase)
<b>Protein</b>	protein serine/threonine phosphatase (Flybase)
<b>Protein domains</b>	Protein phosphatase 2C subfamily, Sigma factor PP2C-like phosphatase, Serine/threonine phosphatases 2C catalytic domain, Protein serine/threonine phosphatase 2C (Flybase)
<b>InterPro analysis</b>	Protein phosphatase 2C-like (IPR001932)
<b>Drosophila functional data</b>	not described (Flybase)
<b>Locus</b>	X, 4D1 (Flybase); X, 4C8 (Gadfly release 2)
<b>Ests</b>	few including LD34192
<b>CDNA</b>	AA979569 (625 base pairs mRNA, 2001), AW943219 (520 base pairs mRNA, 2001), AY069593 (5259 base pairs mRNA, 2001; protein:AAL39738), U96697 (5171 base pairs mRNA, 1998; protein:AAC28998) (Flybase)
<b>genomic DNA</b>	AE003431 (311464 base pairs DNA, 2000; protein:AAF45974) (Flybase)
<b>NCBI locus ID</b>	31404, Dm Pp2C1, Protein phosphatase 2C, 4D1 Aliases: PP2C1, CG2984, dpp2c1, CT10079 RefSeq: NM_080335 Nucleotide: AE003431, AW943219, AY069593, U96697 Protein: AAC28998, AAF45974, AAL39738, NP_525074
<b>Drosophila mutations and mutants</b>	not described (Flybase)

**Example 3: Identification of the human protein phosphatase 2C homologous proteins and genes**

Protein phosphatase 2C homologous proteins and nucleic acid molecules coding therefore are obtainable from insect or vertebrate species, e.g. mammals or birds. Particularly preferred are nucleic acids comprising *Drosophila* protein phosphatase 2C or human protein phosphatase 2C homologs. Sequences homologous to *Drosophila* protein phosphatase 2C were identified using the publicly available program BLASTP 2.2.3 of the non-redundant protein data base of the National Center for Biotechnology Information (NCBI) (see, Altschul et al., 1997, *Nucleic Acids Res.* 25:3389-3402). Table 2 shows the best human homologs of the *Drosophila* protein phosphatase 2C genes.

The term "polynucleotide comprising the nucleotide sequence as shown in GenBank Accession number" relates to the expressible gene of the nucleotide sequences deposited under the corresponding GenBank Accession number. The term "GenBank Accession number" relates to NCBI GenBank database entries (Ref.: Benson et al., *Nucleic Acids Res.* 28 (2000) 15-18). The term "IPI Accession Number" relates to ENSEMBL International Protein Index entries (<http://www.ensembl.org/IPI/>; Hubbard T. et al., (2002) *Nucleic Acids Research* 30 (1): 38-41)

Table 2. Human homologous proteins to *Drosophila* protein phosphatase 2C protein

**PPM1D**

NCBI (National Center for Biotechnology Information) human locus identification (ID): 8493, Hs PPM1D, protein phosphatase 1D magnesium-dependent, delta, 17q23.1

Aliases: WIP1, Wip1

OMIM: 605100



RefSeq: GenBank Accession Number NM\_003620

Nucleotide: GenBank Accession Numbers BC016480, BC033893, U78305

Protein: GenBank Accession Numbers AAB61637, AAH16480, AAH33893, NP\_003611

5

The mouse homologous cDNA encoding the polypeptide of the invention was identified as GenBank Accession Number NM\_016910 (for the mouse homolog of Ppm1d, Wip1).

10

Example 4: Expression of the polypeptides in mammalian (mouse) tissues

15

20

25

To analyse the expression of the polypeptides disclosed in this invention in mammalian tissues, several mouse strains (preferably mice strains C57Bl/6J, C57Bl/6 ob/ob and C57Bl/KS db/db which are standard model systems in obesity and diabetes research) were purchased from Harlan Winkelmann (33178 Borcheln, Germany) and maintained under constant temperature (preferably 22°C), 40 per cent humidity and a light / dark cycle of preferably 14 / 10 hours. The mice were fed a standard chow (for example, from ssniff Spezialitäten GmbH, order number ssniff M-Z V1126-000). For the fasting experiment ("fasted wild type mice"), wild type mice were starved for 48 h without food, but only water supplied ad libitum (see, for example, Schnetzler et al. J Clin Invest 1993 Jul;92(1):272-80, Mizuno et al. Proc Natl Acad Sci U S A 1996 Apr 16;93(8):3434-8). Animals were sacrificed at an age of 6 to 8 weeks. The animal tissues were isolated according to standard procedures known to those skilled in the art, snap frozen in liquid nitrogen and stored at -80°C until needed.

30

For analyzing the role of the proteins disclosed in this invention in the vitro differentiation of different mammalian cell culture cells for the conversion of pre-adipocytes to adipocytes, mammalian fibroblast (3T3-L1)

cells (e.g., Green & Kehinde, Cell 1: 113-116, 1974) were obtained from the American Tissue Culture Collection (ATCC, Hanassas, VA, USA; ATCC- CL 173). 3T3-L1 cells were maintained as fibroblasts and differentiated into adipocytes as described in the prior art (e.g., Qiu. et al.,  
5 J. Biol. Chem. 276:11988-95, 2001; Sliker et al., BBRC 251: 225-9, 1998). In brief, cells were plated in DMEM/10% FCS (Invitrogen, Karlsruhe, Germany) at 50,000 cells/well in duplicates in 6-well plastic dishes and cultured in a humidified atmosphere of 5% CO<sub>2</sub> at 37°C. At confluence (defined as day 0: d0) cells were transferred to serum-free (SF)  
10 medium, containing DMEM/HamF12 (3:1; Invitrogen), fetuin (300 µg/ml; Sigma, Munich, Germany), transferrin (2 µg/ml; Sigma), pantothenate (17µM; Sigma), biotin (1µM; Sigma), and EGF (0.8nM; Hoffmann-La Roche, Basel, Switzerland). Differentiation was induced by adding dexamethasone (DEX; 1µM; Sigma), 3-methyl-isobutyl-1-methylxanthine (MIX; 0.5mM; Sigma), and bovine insulin (5µg/ml; Invitrogen). Four days after confluence  
15 (d4), cells were kept in SF medium, containing bovine Insulin (5µg/ml) until differentiation was completed. At various time points of the differentiation procedure, beginning with day 0 (day of confluence) and day 2 (hormone addition; for example, dexamethasone and 3-isobutyl-1-methylxanthine), up to 10 days of differentiation, suitable aliquots of cells were taken every  
20 two days.

RNA was isolated from mouse tissues or cell culture cells using Trizol Reagent (for example, from Invitrogen, Karlsruhe, Germany) and further  
25 purified with the RNeasy Kit (for example, from Qiagen, Germany) in combination with an DNase-treatment according to the instructions of the manufacturers and as known to those skilled in the art. Total RNA was reverse transcribed (preferably using Superscript II RNaseH- Reverse Transcriptase, from Invitrogen, Karlsruhe, Germany) and subjected to  
30 Taqman analysis preferably using the Taqman 2xPCR Master Mix (from Applied Biosystems, Weiterstadt, Germany; the Mix contains according to the Manufacturer for example AmpliTaq Gold DNA Polymerase, AmpErase

UNG, dNTPs with dUTP, passive reference Rox and optimized buffer components) on a GeneAmp 5700 Sequence Detection System (from Applied Biosystems, Weiterstadt, Germany).

5

Example 5: In vitro assays for the determination of triglyceride and glycogen storage

10 Obesity is known to be caused by different reasons such as non-insulin dependent diabetes, increase in triglycerides, increase in carbohydrate bound energy and low energy expenditure. For example, an increase in energy expenditure (and thus, lowering the body weight) would include the elevated utilization of both circulating and intracellular glucose and triglycerides, free or stored as glycogen or lipids as fuel for energy and/or  
15 heat production. In this invention, we therefore show the cellular level of triglycerides and glycogen in cells overexpressing the protein of the invention.

#### Retroviral infection of preadipocytes

20 Packaging cells were transfected with retroviral plasmids pLPCX carrying the mouse transgene encoding a protein of the invention and a selection marker using calcium phosphate procedure. Control cells were infected with pLPCX carrying no transgene. Briefly, exponentially growing packaging cells were seeded at a density of 350,000 cells per 6-well in 2  
25 ml DMEM + 10 % FCS one day before transfection. 10 min before transfection chloroquine was added directly to the overlying medium (25  $\mu$ M end concentration). A 250  $\mu$ l transfection mix consisting of 5  $\mu$ g plasmid-DNA (candidate:helper-virus in a 1:1 ratio) and 250 mM  $\text{CaCl}_2$  was prepared in a 15 ml plastic tube. The same volume of 2 x HBS (280  $\mu$ M  
30 NaCl, 50  $\mu$ M HEPES, 1.5 mM  $\text{Na}_2\text{HPO}_4$ , pH 7.06) was added and air bubbles were injected into the mixture for 15 sec. The transfection mix was added drop wise to the packaging cells, distributed and the cells were

incubated at 37°C, 5 % CO<sub>2</sub> for 6 hours. The cells were washed with PBS and the medium was exchanged with 2 ml DMEM + 10 % CS per 6-well. One day after transfection the cells were washed again and incubated for 2 days of virus collection in 1 ml DMEM + 10 % CS per 6-well at 32°C,  
5 5 % CO<sub>2</sub>. The supernatant was then filtered through a 0.45 µm cellulose acetate filter and polybrene (end concentration 8 µg/ml) was added. Mammalian fibroblast (3T3-L1) cells in a sub-confluent state were overlaid with the prepared virus containing medium. The infected cells were selected for 1 week with 2 µg/ml puromycin. Following selection the cells  
10 were checked for transgene expression by western blot and immunofluorescence. Over expressing cells were seeded for differentiation.

3T3-L1 cells were maintained as fibroblasts and differentiated into adipocytes as described in the prior art and supra. For analysing the role of  
15 the proteins disclosed in this invention in the in vitro assays for the determination of triglyceride storage, synthesis and transport were performed.

Preparation of cell lysates for analysis of metabolites  
20 Starting at confluence (do), cell media was changed every 48 hours. Cells and media were harvested 8 hours prior to media change as follows. Media was collected, and cells were washed twice in PBS prior to lyses in 600 µl HB-buffer (0.5% polyoxyethylene 10 tridecylethane, 1 mM EDTA, 0.01M NaH<sub>2</sub>PO<sub>4</sub>, pH 7.4). After inactivation at 70°C for 5 minutes, cell lysates  
25 were prepared on Bio 101 systems lysing matrix B (0.1 mm silica beads; Q-Biogene, Carlsbad, USA) by agitation for 2 x 45 seconds at a speed of 4.5 (Fastprep FP120, Bio 101 Thermosavant, Holbrook, USA). Supernatants of lysed cells were collected after centrifugation at 3000 rpm for 2 minutes, and stored in aliquots for later analysis at -80°C.

30

Changes in cellular triglyceride levels during adipogenesis

Cell lysates and media were simultaneously analysed in 96-well plates for total protein and triglyceride content using the Bio-Rad DC Protein assay reagent (Bio-Rad, Munich, Germany) according to the manufacturer's instructions and a modified enzymatic triglyceride kit (GPO-Trinder; Sigma) briefly final volumes of reagents were adjusted to the 96-well format as follows: 10  $\mu$ l sample was incubated with 200  $\mu$ l reagent A for 5 minutes at 37°C. After determination of glycerol (initial absorbance at 540 nm), 50  $\mu$ l reagent B was added followed by another incubation for 5 minutes at 37°C (final absorbance at 540 nm). Glycerol and triglyceride concentrations were calculated using a glycerol standard set (Sigma) for the standard curve included in each assay.

#### Changes in cellular glycogen levels during adipogenesis

Cell lysates and media were simultaneously analysed in triplicates in 96-well plates for total protein and glycogen content using the Bio-Rad DC Protein assay reagent (Bio-Rad, Munich, Germany) according to the manufacturer's instructions and an enzymatic starch kit from Hoffmann-La Roche (Basel, Switzerland). 10- $\mu$ l samples were incubated with 20- $\mu$ l amyloglucosidase solution for 15 minutes at 60°C to digest glycogen to glucose. The glucose is further metabolised with 100  $\mu$ l distilled water and 100  $\mu$ l of enzyme cofactor buffer and 12  $\mu$ l of enzyme buffer (hexokinase and glucose phosphate dehydrogenase). Background glucose levels are determined by subtracting values from a duplicate plate without the amyloglucosidase. Final absorbance is determined at 340 nm. HB-buffer as blank, and a standard curve of glycogen (Hoffmann-La Roche) were included in each assay. Glycogen content in samples were calculated using a standard curve.

#### Synthesis of lipids during adipogenesis

During the terminal stage of adipogenesis (day 12) cells were analysed for their ability to metabolise lipids. A modified protocol to the method of Jensen et al (2000) for lipid synthesis was established. Cells were washed

3 times with PBS prior to serum starvation in Krebs-Ringer-Bicarbonate-Hepes buffer (KRBH; 134 mM NaCl, 3.5 mM KCl, 1.2 mM  $\text{KH}_2\text{PO}_4$ , 0.5 mM  $\text{MgSO}_4$ , 1.5 mM  $\text{CaCl}_2$ , 5 mM  $\text{NaHCO}_3$ , 10 mM Hepes, pH 7.4), supplemented with 0.1% FCS for 2.5h at 37°C. For insulin-stimulated lipid synthesis, cells were incubated with 1  $\mu\text{M}$  bovine insulin (Sigma; carrier: 0.005N HCl) for 45 min at 37°C. Basal lipid synthesis was determined with carrier only.  $^{14}\text{C}(\text{U})$ -D-Glucose (NEN Life Sciences) in a final activity of 1  $\mu\text{Ci}/\text{Well}/\text{ml}$  in the presence of 5 mM glucose was added for 30 min at 37°C. For the calculation of background radioactivity, 25  $\mu\text{M}$  cytochalasin B (Sigma) was used. All assays were performed in duplicate wells. To terminate the reaction, cells were washed 3 times with ice cold PBS, and lysed in 1 ml 0.1N NaOH. Protein concentration of each well was assessed using the standard Biuret method (Protein assay reagent; Bio-Rad). Total lipids were separated from aqueous phase after overnight extraction in Insta-Fluor scintillation cocktail (Packard Bioscience) followed by scintillation counting.

#### Transport and metabolism of free fatty acids during adipogenesis

During the terminal stage of adipogenesis (d12) cells were analysed for their ability to transport long chain fatty acid across the plasma membrane. A modified protocol to the method of Abumrad et al (1991) (Proc. Natl. Acad. Sci. USA, 1991: 88; 6008-12) for cellular transportation of fatty acid was established. In summary, cells were washed 3 times with PBS prior to serum starvation. This was followed by incubation in KRBH buffer supplemented with 0.1% FCS for 2.5h at 37°C. Uptake of exogenous free fatty acids was initiated by the addition of isotopic media containing non radioactive oleate and ( $^3\text{H}$ )oleate (NEN Life Sciences) complexed to serum albumin in a final activity of 1  $\mu\text{Ci}/\text{Well}/\text{ml}$  in the presence of 5 mM glucose for 30min at room temperature (RT). For the calculation of passive diffusion (PD) in the absence of active transport (AT) across the plasma membrane 20mM of phloretin in glucose free media (Sigma) was added for 30 min at RT. All assays were performed in duplicate wells. To terminate

the active transport 20mM of phloretin in glucose free media was added to the cells. Cells were lysed in 1 ml 0.1N NaOH and the protein concentration of each well were assessed using the standard Biuret method (Protein assay reagent; Bio-Rad). Esterified fatty acids were separated from free fatty acids using overnight extraction in Insta-Fluor scintillation cocktail (Packard Bioscience) followed by scintillation counting.

#### Example 6: Glucose uptake assay

For the determination of glucose uptake, cells were washed 3 times with PBS prior to serum starvation in KRBH buffer supplemented with 0.1 % FCS and 0.5mM glucose for 2.5h at 37°C. For insulin-stimulated glucose uptake, cells were incubated with 1  $\mu$ M bovine insulin (Sigma; carrier: 0.005N HCl) for 45 min at 37°C. Basal glucose uptake was determined with carrier only. Non-metabolizable 2-Deoxy-<sup>3</sup>H-D-Glucose (NEN Life Science, Boston, USA) in a final activity of 0,4  $\mu$ Ci/Well/ml was added for 30 min at 37°C. For the calculation of background radioactivity, 25  $\mu$ M cytochalasin B (Sigma) was used. All assays were performed in duplicate wells. To terminate the reaction, cells were washed 3 times with ice cold PBS, and lysed in 1 ml 0.1N NaOH. Protein concentration of each well was assessed using the standard Biuret method (Protein assay reagent; Bio-Rad), and scintillation counting of cell lysates in 10 volumes Ultima-gold cocktail (Packard Bioscience, Groningen, Netherlands) was performed.

#### Example 7: Generation and analysis of protein phosphatase 2C transgenic mice

##### Generation of the transgenic animals

Mouse protein phosphatase 2C cDNA was isolated from mouse brown adipose tissue (BAT) using standard protocols as known to those skilled in the art. The cDNA was amplified by RT-PCR and point mutations were introduced into the cDNA.

The resulting mutated cDNA was cloned into a suitable transgenic expression vector. The transgene was microinjected into the male pronucleus of fertilized mouse embryos (preferably strain C57/BL6/CBA F1 (Harlan Winkelmann)). Injected embryos were transferred into  
5 pseudo-pregnant foster mice. Transgenic founders were detected by PCR analysis. Two independent transgenic mouse lines containing the construct were established and kept on a C57/BL6 background. Briefly, founder animals were backcrossed with C57/BL6 mice to generate F1 mice for analysis. Transgenic mice were continuously bred onto the C57/BL6  
10 background. The expression of the proteins of the invention can be analyzed by taqman analysis as described above, and further analysis of the mice can be done as known to those skilled in the art.



**Claims**

1. A pharmaceutical composition comprising a nucleic acid molecule  
5 encoding protein phosphatase 2C or protein phosphatase 2C  
homologs or a polypeptide encoded thereby or encoded by a  
fragment or a variant of said nucleic acid molecule or said  
polypeptide or an effector of said nucleic acid molecule or said  
polypeptide, preferably together with pharmaceutically acceptable  
10 carriers and diluents.
2. The composition of claim 1, wherein the nucleic acid molecule is a  
vertebrate or insect protein phosphatase 2C nucleic acid, particularly  
encoding the human protein phosphatase 2C homologs (such as  
15 human magnesium-dependent protein phosphatase 1D), and/or a  
nucleic molecule which is complementary thereto or a fragment  
thereof or a variant thereof.
3. The composition of claim 1 or 2, wherein said nucleic acid molecule  
20 is selected from the group consisting of
- (a) a nucleic acid molecule encoding a polypeptide as deposited  
under GenBank Accession Number NM\_003620, or an  
isoform, fragment or variant of the polypeptide as deposited  
under GenBank Accession Number NP\_003611;
  - 25 (b) a nucleic acid molecule which comprises or is the nucleic acid  
molecule as deposited under GenBank Accession Number  
NM\_003620,
  - (c) a nucleic acid molecule being degenerate with as a result of  
the genetic code to the nucleic acid sequences as defined in  
30 (a) or (b),
  - (d) a nucleic acid molecule that hybridizes at 50°C in a solution  
containing 1 x SSC and 0.1% SDS to a nucleic acid molecule

as defined in claim 2 or as defined in (a) to (c) and/or a nucleic acid molecule which is complementary thereto;

(e) a nucleic acid molecule that encodes a polypeptide which is at least 85%, preferably at least 90%, more preferably at least 95%, more preferably at least 98% and up to 99,6% identical to the human magnesium-dependent protein phosphatase 1D variants, as defined in claim 2 or to a polypeptide as defined in (a);

(f) a nucleic acid molecule that differs from the nucleic acid molecule of (a) to (e) by mutation and wherein said mutation causes an alteration, deletion, duplication or premature stop in the encoded polypeptide.

4. The composition of any one of claims 1-3, wherein the nucleic acid molecule is a DNA molecule, particularly a cDNA or a genomic DNA.

5. The composition of any one of claims 1-4, wherein said nucleic acid encodes a polypeptide contributing to regulating the energy homeostasis and/or the metabolism of triglycerides.

6. The composition of any one of claims 1-5, wherein said nucleic acid molecule is a recombinant nucleic acid molecule.

7. The composition of any one of claims 1-6, wherein the nucleic acid molecule is a vector, particularly an expression vector.

8. The composition of any one of claims 1-5, wherein the polypeptide is a recombinant polypeptide.

9. The composition of claim 8, wherein said recombinant polypeptide is a fusion polypeptide.

10. The composition of any one of claims 1-7, wherein said nucleic acid molecule is selected from hybridization probes, primers and anti-sense oligonucleotides.
- 5 11. The composition of any one of claims 1-10 which is a diagnostic composition.
12. The composition of any one of claims 1-10 which is a therapeutic composition.
- 10 13. The composition of any one of claims 1-12 for the manufacture of an agent for detecting and/or verifying, for the treatment, alleviation and/or prevention of metabolic diseases or dysfunctions, for example, but not limited to, metabolic syndrome including obesity, diabetes mellitus, eating disorder, cachexia, hypertension, coronary heart disease, hypercholesterolemia (dyslipidemia), and gallstones, and others, in cells, cell masses, organs and/or subjects.
- 15 14. Use of a nucleic acid molecule of the protein phosphatase 2C gene family or a polypeptide encoded thereby or a fragment or a variant of said nucleic acid molecule or said polypeptide or an effector of said nucleic or polypeptide for controlling the function of a gene and/or a gene product which is influenced and/or modified by a protein phosphatase 2C homologous polypeptide.
- 20 15. Use of the nucleic acid molecule of the protein phosphatase 2C gene family or use of a nucleic acid molecule encoding protein phosphatase 2C or protein phosphatase 2C homologs or use of a polypeptide encoded thereby, or use of a fragment or a variant of said nucleic acid molecule or said polypeptide, or use of an effector of said nucleic acid molecule or said polypeptide for identifying
- 25 30

substances capable of interacting with a protein phosphatase 2C homologous polypeptide.

5 16. A non-human transgenic animal exhibiting a modified expression of a protein phosphatase 2C homologous polypeptide.

17. The animal of claim 16, wherein the expression of the protein phosphatase 2C homologous polypeptide is increased and/or reduced.

10 18. A recombinant host cell exhibiting a modified expression of a protein phosphatase 2C homologous polypeptide, or a recombinant host cell which comprises a nucleic acid molecule as defined in any one of claims 1 to 6.

15 19. The cell of claim 18 which is a human cell.

20 20. A method of identifying a (poly)peptide involved in the regulation of energy homeostasis and/or metabolism of triglycerides in a mammal comprising the steps of

(a) contacting a collection of (poly)peptides with a protein phosphatase 2C homologous polypeptide or a fragment thereof under conditions that allow binding of said (poly)peptides;

25 (b) removing (poly)peptides which do not bind and

(c) identifying (poly)peptides that bind to said protein phosphatase 2C homologous polypeptide.

30 21. A method of screening for an agent which modulates the interaction of a protein phosphatase 2C homologous polypeptide with a binding target/agent, comprising the steps of

(a) incubating a mixture comprising

- (aa) a protein phosphatase 2C homologous polypeptide or a fragment thereof;
- (ab) a binding target/agent of said protein phosphatase 2C homologous polypeptide or fragment thereof; and
- 5 (ac) a candidate agent  
under conditions whereby said protein phosphatase 2C homologous polypeptide or fragment thereof specifically binds to said binding target/agent at a reference affinity;
- 10 (b) detecting the binding affinity of said protein phosphatase 2C homologous polypeptide or fragment thereof to said binding target to determine an (candidate) agent-biased affinity; and
- (c) determining a difference between (candidate) agent-biased affinity and the reference affinity.

15 22. A method of screening for an agent, which modulates the activity of a protein phosphatase 2C homologous polypeptide, comprising the steps of

- (a) incubating a mixture comprising
  - 20 (aa) a protein phosphatase 2C homologous polypeptide or a fragment thereof;
  - (ab) a candidate agent  
under conditions whereby said protein phosphatase 2C homologous polypeptide or fragment thereof exhibits a reference activity;
- 25 (b) detecting the activity of said protein phosphatase 2C homologous polypeptide or fragment thereof to determine a (candidate) agent-biased activity and
- (c) determining a difference between (candidate) agent-biased activity and reference activity.

30

23. A method of producing a composition comprising the (poly)peptide identified by the method of claim 20 or the agent identified by the

method of claim 21 or 22 with a pharmaceutically acceptable carrier, diluent and/or adjuvant.

- 5 24. The method of claim 23 wherein said composition is a pharmaceutical composition for preventing, alleviating or treating of diseases and disorders, including metabolic diseases or dysfunctions, for example, but not limited to, such as metabolic syndrome including obesity, diabetes mellitus, eating disorder, cachexia, hypertension, coronary heart disease, hypercholesterolemia (dyslipidemia), and gallstones, and other  
10 diseases and disorders.
- 15 25. Use of a (poly)peptide as identified by the method of claim 20 or of an agent as identified by the method of claim 21 or 22 for the preparation of a pharmaceutical composition for the treatment, alleviation and/or prevention of of diseases and disorders, including metabolic diseases or dysfunctions, for example, but not limited to, metabolic syndrome including obesity, diabetes mellitus, eating disorder, cachexia, hypertension, coronary heart disease, hypercholesterolemia (dyslipidemia), and gallstones, and other  
20 diseases and disorders.
- 25 26. Use of a nucleic acid molecule as defined in any one of claims 1 to 6 or 10, use of a polypeptide as defined in any one of claims 1 to 6, 8 or 9, use of a vector as defined in claim 7, use of a host cell as defined in claim 18 or 19 for the preparation of a pharmaceutical composition for the treatment, alleviation and/or prevention of of diseases and disorders, including metabolic diseases or dysfunctions, for example, but not limited to, metabolic syndrome  
30 including obesity, diabetes mellitus, eating disorder, cachexia, hypertension, coronary heart disease, hypercholesterolemia (dyslipidemia), and gallstones, and other diseases and disorders.

27. Use of a nucleic acid molecule of the protein phosphatase 2C gene family or of a fragment thereof for the preparation of a non-human animal which over- or under-expresses the protein phosphatase 2C gene product.

5

28. Kit comprising at least one of

- (a) a protein phosphatase 2C nucleic acid molecule or a fragment or an isoform thereof;
- (b) a protein phosphatase 2C amino acid molecule or a fragment or an isoform thereof;
- (c) a vector comprising the nucleic acid of (a);
- (d) a host cell comprising the nucleic acid of (a) or the vector of (b);
- (e) a polypeptide encoded by the nucleic acid of (a), expressed by the vector of (c) or the host cell of (a);
- (f) a fusion polypeptide encoded by the nucleic acid of (a);
- (g) an antibody, an aptamer or another effector against the nucleic acid of (a) or the polypeptide of (b) , (e) , or (f) and /or
- (h) an anti-sense oligonucleotide of the nucleic acid of (a).

10

15

20

- 53 -

EPO - Munich  
5

20. Dez. 2002

**Abstract**

5 The present invention discloses protein phosphatase 2C homologous  
proteins regulating the energy homeostasis and the metabolism of  
triglycerides, and polynucleotides, which identify and encode the proteins  
disclosed in this invention. The invention also relates to the use of these  
sequences in the diagnosis, study, prevention, and treatment of metabolic  
diseases and disorders.

10

Id 20.12.2002



20. Dez. 2002

20. Dez. 2002

FIGURE 1. Glycogen content of a *Drosophila* protein phosphatase 2C (Pp2C1) mutant





Figure 2. Molecular organization of the Pp2C1 gene (GadFly Accession Number CG2984)



**FIGURE 3. Nucleic acid sequences and amino acid sequences of the human protein phosphatase 1D magnesium-dependent, delta isoform (PPM1D)**

**FIGURE 3A. Homo sapiens protein phosphatase 1D magnesium-dependent, delta isoform (PPM1D), Nucleic acid sequence (SEQ ID NO: 1)**

```

1  ctggctctgc  tcgctccggc  gctccggccc  agctctcgcg  gacaagtcca  gacatcgcgc
61  gccccccctt  ctccgggtcc  gccccctccc  ccttctcggc  gtcgtcgaag  ataaacaata
121  gttggccggc  gagegcctag  tgtgtctccc  gccgcgggat  tcggcgggct  gcgtgggacc
181  ggccggatcc  cggccagccg  gccatggcgg  ggctgtactc  gctgggagtg  agcgtcttct
241  ccgaccaggg  cgggaggaag  tacatggagg  acgttactca  aatcgttgtg  gagcccgaac
301  cgacggctga  agaaaagccc  tcgccgcggc  ggctcgctgtc  tcagccgttg  cctccgcggc
361  cgctcgccgg  cgcccttccc  ggccggcgaag  tctcggggaa  aggcccagcg  gtggcagccc
421  gagaggctcg  cgacctctc  ccggacgcgg  gggcctcgcc  ggacacctag  cgctgctgcc
481  gccgccgttc  ctccgtggcc  tttttcgccg  tgtgcgacgg  gcacggcggg  cgggaggcgg
541  cacagtttgc  ccgggagcac  ttgtgggggt  tcatcaagaa  gcagaagggt  ttcacctcgt
601  ccgagccggc  taaggtttgc  gctgccatcc  gcaaaggctt  tctcgcttgt  caccttgcca
661  tgtggaagaa  actggcggaa  tggccaaaga  ctatgacggg  tcttcctagc  acatcagggg
721  caactgccag  tgtgttcate  attcgggggc  tgaagatgta  tgtagctcac  gtaggtgact
781  caggggtggt  tcttggaatt  caggatgacc  cgaaggatga  ctttgtcaga  gctgtggagg
841  tgacacagga  ccataagcca  gaacttccc  aggaaagaga  acgaatcgaa  ggacttggtg
901  ggagtgtaat  gaacaagtct  ggggtgaatc  gtgtagtttg  gaaacgacct  cgactcactc
961  acaatggacc  tgttagaagg  agcacagtta  ttgaccagat  tccttttctg  gcagtagcaa
1021  gagcacttgg  tgatttgtgg  agctatgatt  tottcagtgg  tgaatttgtg  gtgtcacctg
1081  aaccagacac  aagtgtccac  actcttgacc  ctcagaagca  caagtatat  atattgggga
1141  gtgatggact  ttggaatatg  attccaccac  aagatgccat  ctcaatgtgc  caggaccaag
1201  aggagaaaaa  atacctgatg  ggtgagcatg  gacaatcttg  tgccaaaatg  cttgtgaaac
1261  gagcattggg  ccgctggagg  cagcgtatgc  tccgagcaga  taacactagt  gccatagtaa
1321  tctgcatctc  tccagaagtg  gacaatcagg  gaaactttac  caatgaagat  gagttatacc
1381  tgaacctgac  tgacagccct  tcctataata  gtcaagaaac  ctgtgtgatg  actccttccc
1441  catgttctac  accaccagtc  aagtcactgg  aggaggatcc  atggccaagg  gtgaattcta
1501  aggaccatat  acctgccctg  gttcgtagca  atgccttctc  agagaatttt  ttagagggtt
1561  cagctgagat  agctcgagag  aatgtccaag  gtgtagtcac  accctcaaaa  gatccagaac
1621  cacttgaaga  aaattgcgct  aaagccctga  ctttaaggat  acatgattct  ttaataata
1681  gccttccaat  tggccttgtg  cctactaata  caacaaacac  tgtcatggac  caaaaaaatt
1741  tgaagatgtc  aactcctggc  caaatgaaag  cccaagaaat  tgaaagaacc  cctccaacaa
1801  actttaaaag  gacattagaa  gagtccaatt  ctggccccct  gatgaagaag  catagacgaa
1861  atggcttaag  tcgaagtagt  ggtgctcagc  ctgcaagtct  cccacaacc  tcacagcgaa
1921  agaactctgt  taaactcacc  atgcgacgca  gacttagggg  ccagaagaaa  attggaaatc
1981  ctttacttca  tcaacacagg  aaaactggtt  gtgtttgctg  aaatgcatct  gggaaatgag
2041  gtttttccaa  acttaggata  taagagggct  ttttaaattt  ggtgccgatg  ttgaactttt
2101  ttttaagggg  gaaaattaaa  agaaatatac  agtttgactt  tttggaattc  agcagtttta
2161  tcctggcctt  gtacttgctt  gtattgtaaa  tgtggatttt  gtagatgta  ggggtataag
2221  tgctgtaaaa  tttgtgtaaa  tttgtatcca  caciaaattc  gtctctgaat  acacagtatt
2281  cagagtctct  gatacacagt  aattgtgaca  atagggtcaa  atgtttaaag  aaatcaaaag
2341  aatctattag  atttttagaa  aacatttaaa  ctttttaaaa  tacttattaa  aaaatttgta
2401  taagccactt  gtcttgaaaa  ctgtgcaact  ttttaaagta  aattattaa  cagactggaa
2461  aagtgatgta  ttttcatagt  gacctgtgtt  tcacttaatg  tttcttagag  ccaagtgtct
2521  tttaaacatt  attttttatt  tctgatttca  taattcagaa  ctaaaatttt  ctataagtg
2581  ttgagccatg  ctacagttag  tcttgtccca  attaaaatac  tatgcagtat  ctcttacatc
2641  agtagcattt  ttctaaaacc  ttagtcatca  gatatgctta  ctaaatcttc  agcatagaag
2701  gaagtgtggt  tgcctaaaa  aatctaaaac  aattcccttc  tttttcatcc  cagaccaatg
2761  gcattattag  gtcttaaaag  agttactccc  ttctcgtgtt  tgcttaaaat  atgtgaagtt
2821  ttccttgcta  tttcaataac  agatggtgct  gctaattccc  aacatttctt  aaattatttt
2881  atatcataca  gttttcattg  attatatggg  tatatattca  tctaataaat  cagtgaactg
2941  ttcctcatgt  tgctgaaaaa  aaaaaaaaaa  aaa

```

**FIGURE 3B. Homo sapiens protein phosphatase 1D magnesium-dependent, delta isoform (PPM1D), Amino acid sequence (SEQ ID NO: 2)**

```
1  maglyslgvs vfsdqggrky medvtqivve peptaeekps prrslsqplp prpspaalpg
61  gevsgkgpav aareardplp dagaspapsr crrrrssvaf favcdghggr eaaqfarehl
121 wgfikkkqkf tssepakvca airkgflach lamwkklaew pktmtglpst sgttasvvii
181 rgmkmyvahv gdsgvvlgiq ddpkddfvra vevtqdhkpe lpkererieg lggsvmnksg
241 vnrvvwkrpr lthngpvrrs tvidqipfla varalgdlls ydfffgefvy spepdtsvht
301 ldpqkhkyii lgsdglwnmi ppqdaismcq dgeekkyllm ehgqscakml vnralgrwrq
361 rmlradntsa ivicispevd nqgnftnde lylntdsps ynsqetcvmt pspcstppvk
421 sleedpwprv nskdhipalv rsnafsenfl evsaeiaren vggvipskd pepleencak
481 altlrihdsi nnspliglpv tnstntvmdq knlkmstpgg mkaqeiertp ptnfkrtlee
541 snsgplmkkh rrnglsrsgg aqpaslptts qrknsvklm rrrlrgqkki gnp1lhqhrk
601 tvcvc
```

**THIS PAGE BLANK (USPTO)**

PCT Application

**PCT/EP2003/014344**



**This Page is Inserted by IFW Indexing and Scanning  
Operations and is not part of the Official Record**

**BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

☐ **BLACK BORDERS**

☐ **IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**

☐ **FADED TEXT OR DRAWING**

☒ **BLURRED OR ILLEGIBLE TEXT OR DRAWING**

☐ **SKEWED/SLANTED IMAGES**

☐ **COLOR OR BLACK AND WHITE PHOTOGRAPHS**

☐ **GRAY SCALE DOCUMENTS**

☐ **LINES OR MARKS ON ORIGINAL DOCUMENT**

☐ **REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**

☐ **OTHER:** \_\_\_\_\_

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.**